Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Jones

Showing results (331-340 of 363) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2025
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trialMatthew Tate, Christopher J R Illingworth, Gordon MacGregor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Neuroimage. Clinical|April 28, 2020
Image acquisition and quality assurance in the Boston Adolescent Neuroimaging of Depression and Anxiety studyViviana Siless, Nicholas A Hubbard, Robert Jones, et al.
Surgery|March 22, 2024
Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?Rami Rhaiem, Adrien Duramé, Florian Primavesi, et al.
British Journal of Cancer|November 8, 2025
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodologyRichard Phillips, Bristi Basu, Zohra Butt, et al.
Faraday Discussions|October 17, 2017
Supramolecular effects in self-assembled monolayers: general discussionDavid Amabilino, Ioan Bâldea, James Batteas, et al.
Health Technology Assessment (Winchester, England)|September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCTFiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Pageof 37

Showing results (331-340 of 363) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2025
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trialMatthew Tate, Christopher J R Illingworth, Gordon MacGregor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
Neuroimage. Clinical|April 28, 2020
Image acquisition and quality assurance in the Boston Adolescent Neuroimaging of Depression and Anxiety studyViviana Siless, Nicholas A Hubbard, Robert Jones, et al.
Surgery|March 22, 2024
Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?Rami Rhaiem, Adrien Duramé, Florian Primavesi, et al.
British Journal of Cancer|November 8, 2025
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodologyRichard Phillips, Bristi Basu, Zohra Butt, et al.
Faraday Discussions|October 17, 2017
Supramolecular effects in self-assembled monolayers: general discussionDavid Amabilino, Ioan Bâldea, James Batteas, et al.
Health Technology Assessment (Winchester, England)|September 9, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCTFiona Collinson, Kara-Louise Royle, Jayne Swain, et al.
Pageof 37